Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? (2013)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- Subjects: NEOPLASIAS COLORRETAIS; METÁSTASE NEOPLÁSICA; ANTICORPOS MONOCLONAIS; QUIMIOTERAPIA (EFEITOS)
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2013
- Source:
- Título do periódico: Current colorectal cancer reports
- ISSN: 1556-3790
- Volume/Número/Paginação/Ano: v. 9, n. 4, p. 317-325, 2013
-
ABNT
BRAGHIROLI, Maria Ignez et al. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same?. Current colorectal cancer reports, v. 9, n. 4, p. 317-325, 2013Tradução . . Disponível em: http://dox.doi.org/10.1007/s11888-013-0187-0. Acesso em: 27 jan. 2023. -
APA
Braghiroli, M. I., Riechelmann, R. P., Sabbaga, J., & Hoff, P. M. G. (2013). Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? Current colorectal cancer reports, 9( 4), 317-325. Recuperado de http://dox.doi.org/10.1007/s11888-013-0187-0 -
NLM
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2023 jan. 27 ] Available from: http://dox.doi.org/10.1007/s11888-013-0187-0 -
Vancouver
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2023 jan. 27 ] Available from: http://dox.doi.org/10.1007/s11888-013-0187-0 - TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
- Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
- Building research capacity and clinical trials in developing countries
- Living better or living longer? perceptions of patients (PTS) and health care professionals (HCP) in ONCOLOGY
- Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
- Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
- Análise restrospectiva de desfechos clínicos e fatores prognósticos em pacientes com carcinomatose meníngea
- Revisão de processos reduz tempo de implementação de estudos clínicos no Instituto do Câncer do Estado de São Paulo
- Estudo retrospectivo de prevalência de instabilidade de microssatélite em pacientes com câncer colorretal (CCR) não selecionados submetidos a cirurgia do tumor primário: análise de 212 pacientes do Instituto do Câncer do Estado de São Paulo - ICESP
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
